首页> 外文期刊>Nephron >An intron 4 gene polymorphism in endothelial cell nitric oxide synthase might modulate lipid metabolism in nondiabetic patients on hemodialysis.
【24h】

An intron 4 gene polymorphism in endothelial cell nitric oxide synthase might modulate lipid metabolism in nondiabetic patients on hemodialysis.

机译:内皮细胞一氧化氮合酶中的内含子4基因多态性可能会调节血液透析中非糖尿病患者的脂质代谢。

获取原文
获取原文并翻译 | 示例
           

摘要

We investigated the relationship between endothelial constitutive nitric oxide synthase (ecNOS) gene polymorphism and lipid metabolism in patients with nondiabetic chronic renal failure on hemodialysis. Serum from 181 nondiabetic patients on hemodialysis were examined. A genomic DNA fragment was amplified by polymerase chain reaction (PCR) for determining the ecNOS genotype. The PCR products were designated as a and b alleles by electrophoresis. In hemodialysis patients, the frequency of the ecNOS4 for b/b, b/a and a/a genotype was 76.6, 22.8 and 0.6%, respectively. There was not significant difference in the levels of total cholesterol (TC), triglyceride (TG) and calculated low-density lipoprotein cholesterol (LDL-c) in sera between patients (aa and ba) with the a allele and patients (bb) without the a allele. On the other hand, the levels of serum high-density lipoprotein cholesterol (HDL-c) in patients with the a allele (51.9 +/- 3.33 mg/dl) were significantly higher than those in patients without the a allele (43.05 +/- 1.40 mg/dl) (p = 0.005). The frequency of patients with the a allele and low levels of serum HDL-c among patients with a long duration of dialysis (> or =10 years) was significantly lower than that in patients with short duration of dialysis (<10 years) (p = 0.05). It appears that an intron 4 gene polymorphism in ecNOS may modulate lipid metabolism in nondiabetic patients on hemodialysis and the a allele of ecNOS gene polymorphism may affect the prognosis of hemodialysis patients with low levels of serum HDL-c.
机译:我们调查了非糖尿病慢性肾衰竭患者血液透析中内皮型一氧化氮合酶(ecNOS)基因多态性与脂质代谢之间的关系。检查了181名接受血液透析的非糖尿病患者的血清。通过聚合酶链反应(PCR)扩增基因组DNA片段,以确定ecNOS基因型。通过电泳将PCR产物命名为a和b等位基因。在血液透析患者中​​,ecNOS4出现在b / b,b / a和a / a基因型中的频率分别为76.6、22.8和0.6%。携带等位基因的患者(aa和ba)与未携带等位基因的患者(bb)之间的血清总胆固醇(TC),甘油三酸酯(TG)和计算出的低密度脂蛋白胆固醇(LDL-c)水平没有显着差异。等位基因。另一方面,等位基因患者(51.9 +/- 3.33 mg / dl)的血清高密度脂蛋白胆固醇(HDL-c)水平显着高于无等位基因患者(43.05 + / -1.40 mg / dl)(p = 0.005)。透析时间长(>或= 10年)的患者中等位基因和血清HDL-c水平低的患者的频率显着低于透析时间短(<10年)的患者(p = 0.05)。似乎在血液透析中,ecNOS中的内含子4基因多态性可能会调节非糖尿病患者的脂质代谢,而ecNOS基因多态性的等位基因可能会影响低血清HDL-c水平的血液透析患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号